Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

PhRMA Statement on FDA User Fees

March 22, 2017

PhRMA president and CEO Stephen J. Ubl issued a statement in support of the U.S. Food and Drug Administration’s (FDA) user fee programs the Prescription Drug User Fee Act (PDUFA) VI, Biosimilar User Fee Act (BsUFA) II and the Generic Drug User Fee Act (GDUFA) II.

Read More

PhRMA Statement on NAFTA Tribunal Decision in the Eli Lilly Case

March 21, 2017

PhRMA issued statement on the NAFTA Tribunal Decision in the Eli Lilly Case.

Read More

PhRMA Statement on Dr. Scott Gottlieb’s Nomination to Lead the U.S. Food and Drug Administration

March 10, 2017

Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement on President Trump’s nomination of Dr. Scott Gottlieb to lead the U.S. Food and Drug Administration (FDA).

Read More

PhRMA Convenes Stakeholders to Discuss Value Assessments and New Ways to Pay for Medicines

February 24, 2017

Leaders across the health care continuum gathered yesterday in Washington, D.C., to discuss ways to improve payment and delivery systems in the private market and opportunities for producing and rewarding better value for patients. The meeting was convened by The Value Collaborative, an initiative of America’s biopharmaceutical companies, in partnership with Morning Consult.

Read More

PhRMA Kicks Off National Health Care Dialogue to Examine the New Era of Medicine

February 21, 2017

PhRMA will sponsor its first national health care dialogue series today in Boston, Massachusetts.

Read More

Scott LaGanga to Lead PhRMA State Advocacy; Shannon Graham to Lead Strategic Alliances

February 3, 2017

PhRMA announced that PhRMA Senior Vice President Scott LaGanga has been named head of PhRMA state advocacy and assumes the responsibilities of Jeff Bond, who announced his retirement from PhRMA. Shannon Graham has been promoted to senior vice president and will lead PhRMA’s advocacy and strategic alliances program.

Read More

PhRMA Board of Directors Elects New Officers, Welcomes New Member Company

January 31, 2017

The Pharmaceutical Research and Manufacturers of America (PhRMA) Board elected new officers and welcomed a new member company today.

Read More

PhRMA Statement Following Meeting With President Trump

January 31, 2017

This morning, we had a positive, productive meeting with President Trump, Vice President Pence and House Energy and Commerce Chairman Greg Walden, (R-Ore.). We talked about how we can work together to improve American competitiveness around the world, create more jobs here at home and enhance the U.S. biopharmaceutical industry that continues to lead the world in the development of lifesaving treatments and cures.

Read More

Las Compañías Biofarmacéuticas de Estados Unidos Lanzan una Innovadora Iniciativa Anunciando la Nueva Era de la Medicina

January 23, 2017

Pharmaceutical Researchers & Manufacturers of America (PhRMA) lanzó hoy una iniciativa nacional, de publicidad y asuntos públicos en nombre de las compañías biofarmacéuticas de los Estados Unidos. La campaña, GOBOLDLY, mostrará a los héroes no reconocidos de la industria, impulsando científicos y resaltando las oportunidades existentes para hacer frente a las condiciones de salud más complejas y devastadoras.

Read More

America’s Biopharmaceutical Companies Launch Groundbreaking, Multi-Year Initiative Heralding New Era of Medicine

January 23, 2017

PhRMA has launched a national, multi-year advertising and public affairs initiative on behalf of America’s biopharmaceutical companies. The campaign, GOBOLDLY, will showcase the industry’s unsung heroes driving cutting-edge advances in science and highlight the tremendous opportunity that exists to tackle our most complex and devastating health conditions.

Read More